NCT05558267Not yet recruiting
Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
A Randomized, Pilot, Double-Blind Crossover Trial of a Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 23 Sept 2022
- Start date
- Jan 2027
- Primary completion date
- Jun 2027
- Lead sponsor
- NYU Langone Health
- Diseases
- Chronic kidney disease
- NCT number
- NCT05558267
What you commit to
- Study type: Interventional
- Planned participants: 20
- From Jan 2027 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Co-habiting family with ≥stage 3b chronic kidney disease or chronic kidney disease of unknown severity.
Lab values
- Non-hemolyzed serum potassium concentration \>6.0 mEq/L within ≤30 days.
- Hemoglobin \< 8.0 mg/dL.
- Use of other potassium supplements.
Other
- Currently incarcerated.
- Insufficient capacity for informed consent.
- Unscheduled HD for hyperkalemia within ≤30 days.
- Attendance at ≤10 of last 13 scheduled OP HD sessions.
- Co-habiting family member with known hyperkalemia.
Who the study is looking for
- Receiving outpatient maintenance HD therapy.
- Age ≥ 21 years.
- Negative serum pregnancy test for women of child-bearing capacity. Childbearing capacity will be defined by report of menstruation within ≤ 6 months.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.